Coya Therapeutics (COYA) Competitors $7.04 -0.19 (-2.63%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends COYA vs. DNA, RNAC, CTNM, FHTX, GHRS, RGNX, FDMT, NLTX, ESPR, and CCCCShould you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Ginkgo Bioworks (DNA), Cartesian Therapeutics (RNAC), Contineum Therapeutics (CTNM), Foghorn Therapeutics (FHTX), GH Research (GHRS), REGENXBIO (RGNX), 4D Molecular Therapeutics (FDMT), Neoleukin Therapeutics (NLTX), Esperion Therapeutics (ESPR), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry. Coya Therapeutics vs. Ginkgo Bioworks Cartesian Therapeutics Contineum Therapeutics Foghorn Therapeutics GH Research REGENXBIO 4D Molecular Therapeutics Neoleukin Therapeutics Esperion Therapeutics C4 Therapeutics Coya Therapeutics (NASDAQ:COYA) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Do analysts rate COYA or DNA? Coya Therapeutics presently has a consensus price target of $16.67, indicating a potential upside of 136.74%. Ginkgo Bioworks has a consensus price target of $4.16, indicating a potential downside of 46.29%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Coya Therapeutics is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Ginkgo Bioworks 3 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Does the MarketBeat Community believe in COYA or DNA? Ginkgo Bioworks received 12 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 92.31% of users gave Coya Therapeutics an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote. CompanyUnderperformOutperformCoya TherapeuticsOutperform Votes1292.31% Underperform Votes17.69%Ginkgo BioworksOutperform Votes2446.15% Underperform Votes2853.85% Does the media prefer COYA or DNA? In the previous week, Coya Therapeutics had 6 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 10 mentions for Coya Therapeutics and 4 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 1.04 beat Coya Therapeutics' score of 0.26 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, COYA or DNA? Coya Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Is COYA or DNA more profitable? Coya Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -486.98%. Coya Therapeutics' return on equity of -35.63% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -35.63% -30.96% Ginkgo Bioworks -486.98%-63.09%-38.13% Which has stronger earnings & valuation, COYA or DNA? Coya Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Coya Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$6M17.86-$7.99M-$0.73-9.64Ginkgo Bioworks$251.46M1.71-$892.87M-$18.40-0.42 Do institutionals & insiders hold more shares of COYA or DNA? 39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryCoya Therapeutics beats Ginkgo Bioworks on 12 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COYA vs. The Competition Export to ExcelMetricCoya TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$107.15M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-9.649.93114.8115.14Price / Sales17.86396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book2.855.324.665.02Net Income-$7.99M$153.56M$119.06M$225.46M7 Day Performance-21.43%0.13%0.80%0.37%1 Month Performance6.83%15.23%5.65%3.57%1 Year Performance46.67%41.14%36.75%29.43% Coya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COYACoya Therapeutics2.3564 of 5 stars$7.04-2.6%$16.67+136.7%+51.7%$107.15M$6M-9.646Analyst ForecastShort Interest ↑News CoverageDNAGinkgo Bioworks0.9417 of 5 stars$7.84+2.9%$4.16-46.9%N/A$435.75M$251.46M-0.431,218Positive NewsRNACCartesian Therapeutics3.3474 of 5 stars$20.17+1.9%$43.00+113.2%N/A$431.44M$26M0.0037Positive NewsCTNMContineum Therapeutics1.4634 of 5 stars$16.76-2.1%$29.50+76.0%N/A$431.12M$50M0.0031Gap UpFHTXFoghorn Therapeutics3.0504 of 5 stars$7.76+1.8%$16.00+106.2%+125.5%$429.36M$34.15M-3.98120Upcoming EarningsGHRSGH Research1.7907 of 5 stars$8.20+1.2%$36.67+347.2%+15.4%$426.65MN/A-12.2410Short Interest ↑News CoverageRGNXREGENXBIO4.5128 of 5 stars$8.60+0.1%$35.45+312.3%-38.1%$425.04M$89.04M-1.63344Upcoming EarningsFDMT4D Molecular Therapeutics2.4306 of 5 stars$8.14+1.6%$47.14+479.2%-24.2%$423.04M$20.72M-3.54201Short Interest ↓NLTXNeoleukin TherapeuticsN/A$44.01+0.6%N/A+240.8%$413.61MN/A-14.1590High Trading VolumeESPREsperion Therapeutics3.9606 of 5 stars$2.04flat$8.17+300.3%+136.3%$400.31M$116.33M-2.37240Upcoming EarningsShort Interest ↓News CoverageCCCCC4 Therapeutics2.2288 of 5 stars$5.66+6.2%$10.50+85.5%+325.0%$392.46M$20.76M-2.98150Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Ginkgo Bioworks Competitors Cartesian Therapeutics Competitors Contineum Therapeutics Competitors Foghorn Therapeutics Competitors GH Research Competitors REGENXBIO Competitors 4D Molecular Therapeutics Competitors Neoleukin Therapeutics Competitors Esperion Therapeutics Competitors C4 Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COYA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
